Two Sigma Investments
ACHL

Two Sigma Investments’s Achilles Therapeutics ACHL Stock Holding History

Two Sigma Investments’s Portfolio ACHL Stock Details ACHL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-61,637
Closed -$70.3K – 3577
2024
Q4 		$70.3K Buy
61,637
+40,388
+190% +$41.6K ﹤0.01% 3010
2024
Q3 		$21.7K Sell
21,249
-229
-1% -$183 ﹤0.01% 3019
2024
Q2 		$17.5K Buy
21,478
+9,679
+82% +$8.51K ﹤0.01% 2938
2024
Q1 		$14.7K Buy
+11,799
New +$12.7K ﹤0.01% 2942

Other funds holding ACHL

XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
BAM
Brave Asset Management Summit, New Jersey $467M AUM 33.05% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return

Two Sigma Investments's ACHL Position: Q1 2025 in Review

Two Sigma Investments sold out of Achilles Therapeutics (ACHL) in Q1 2025, closing a stake of 61,637 shares — an estimated $70.3K sold.

Two Sigma Investments first reported a position in ACHL in Q1 2024 and held it in 4 quarters. The position peaked at $70.3K in Q4 2024. 6 funds tracked by Wall St. Rank hold ACHL as of Q1 2025.

  • Two Sigma Investments reported no remaining Achilles Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Two Sigma Investments sold 61,637 Achilles Therapeutics shares in Q1 2025, an estimated $70.3K.
  • Two Sigma Investments first reported a position in Achilles Therapeutics in Q1 2024 and held it in 4 quarters.
  • Two Sigma Investments's Achilles Therapeutics position peaked at $70.3K in Q4 2024.
  • 6 funds tracked by Wall St. Rank held Achilles Therapeutics as of Q1 2025.

Based on Two Sigma Investments's 13F filing for Q1 2025, filed 15 May 2025.